StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 10:00:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Gilead to present lenacapavir HIV trial data at AIDS 2026 http://www.streetinsider.com/Corporate+News/Gilead+to+present+lenacapavir+HIV+trial+data+at+AIDS+2026/26793784.html <p>Gilead Sciences (NASDAQ: GILD) plans to present data from multiple HIV clinical trials at the 26th International AIDS Conference in Rio de Janeiro, Brazil, running July 26–31, according to a company statement.</p><p>Key presentations include long-term follow-up data from the open-label extension phases of the Phase 3 PURPOSE 1 and PURPOSE 2 trials evaluating twice-yearly lenacapavir as pre-exposure prophylaxis (PrEP). The data cover more than 7,178 person-years of follow-up in PURPOSE 1 and 5,295 in PURPOSE 2. In the PURPOSE 1 extension, no new HIV infections were observed among participants receiving lenacapavir. In PURPOSE 2, one infection was recorded among those http://www.streetinsider.com/Corporate+News/Gilead+to+present+lenacapavir+HIV+trial+data+at+AIDS+2026/26793784.html Tue, 21 Jul 2026 10:00:54 -0400 GILD MRK Gilead to present lenacapavir HIV trial data at AIDS 2026 http://www.streetinsider.com/Corporate+News/Gilead+to+present+lenacapavir+HIV+trial+data+at+AIDS+2026/26793784.html <p>Gilead Sciences (NASDAQ: GILD) plans to present data from multiple HIV clinical trials at the 26th International AIDS Conference in Rio de Janeiro, Brazil, running July 26–31, according to a company statement.</p><p>Key presentations include long-term follow-up data from the open-label extension phases of the Phase 3 PURPOSE 1 and PURPOSE 2 trials evaluating twice-yearly lenacapavir as pre-exposure prophylaxis (PrEP). The data cover more than 7,178 person-years of follow-up in PURPOSE 1 and 5,295 in PURPOSE 2. In the PURPOSE 1 extension, no new HIV infections were observed among participants receiving lenacapavir. In PURPOSE 2, one infection was recorded among those http://www.streetinsider.com/Corporate+News/Gilead+to+present+lenacapavir+HIV+trial+data+at+AIDS+2026/26793784.html Tue, 21 Jul 2026 10:00:54 -0400 GILD MRK Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead and Merck HIV pill shows strong results in Phase 3 trials http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html <p>Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir (ISL/LEN) met primary endpoints at Week 48 in two Phase 3 trials, known as ISLEND-1 and ISLEND-2.</p> <p>In ISLEND-1, no participants who switched to ISL/LEN had HIV-1 RNA at or above 50 copies/mL at Week 48, compared with 0.3% of participants who remained on Gilead's Biktarvy. In ISLEND-2, 0.3% of ISL/LEN participants had HIV-1 RNA at or above 50 copies/mL, versus 1.3% of those continuing standard-of-care daily regimens. Both results were determined using the U.S. FDA-defined snapshot algorithm.</p> <p>The companies said the http://www.streetinsider.com/FDA/Gilead+and+Merck+HIV+pill+shows+strong+results+in+Phase+3+trials/26793767.html Tue, 21 Jul 2026 10:00:23 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Press+Releases/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html <p class="bwalignc"> <b><i>– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials –</i></b> </p><p class="bwalignc"> <b><i>– ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment –</i></b> </p> <p> FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54574108&newsitemid=20260720061462&lan=en-US&anchor=AIDS+2026&index=1&md5=3c2589b74982a0ff0014ced3713928c1" shape="rect">AIDS 2026</a>). The primary endpoint http://www.streetinsider.com/Business+Wire/Investigational+Once-Weekly+Oral+HIV+Treatment+Regimen+of+Islatravir+and+Lenacapavir+Maintained+Virological+Suppression+in+Adults+With+HIV+Who+Switched+Antiretroviral+Therapy/26793736.html Tue, 21 Jul 2026 10:00:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html <p class="bwalignc"> <b><i>–</i></b><i><b> Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP –</b></i> </p><p class="bwalignc"> <b><i>– Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir –</i></b> </p><p class="bwalignc"> <b><i>– Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54573930&newsitemid=20260720642268&lan=en-US&anchor=AIDS+2026&index=1&md5=c84579da5c0a7485df797bac17460af5" shape="rect">AIDS 2026</a>) taking place in Rio http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html Tue, 21 Jul 2026 10:00:00 -0400 A.23317141 A.26378697 A.50200944 GILD MRK O.00037438 O.00043238 O.00092067 O.37220915 O.39182271 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html <p class="bwalignc"> <b><i>–</i></b><i><b> Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP –</b></i> </p><p class="bwalignc"> <b><i>– Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir –</i></b> </p><p class="bwalignc"> <b><i>– Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54573930&newsitemid=20260720642268&lan=en-US&anchor=AIDS+2026&index=1&md5=c84579da5c0a7485df797bac17460af5" shape="rect">AIDS 2026</a>) taking place in Rio http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html Tue, 21 Jul 2026 10:00:00 -0400 A.23317141 A.26378697 A.50200944 GILD MRK O.00037438 O.00043238 O.00092067 O.37220915 O.39182271 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html <p class="bwalignc"> <b><i>–</i></b><i><b> Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP –</b></i> </p><p class="bwalignc"> <b><i>– Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir –</i></b> </p><p class="bwalignc"> <b><i>– Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54573930&newsitemid=20260720642268&lan=en-US&anchor=AIDS+2026&index=1&md5=c84579da5c0a7485df797bac17460af5" shape="rect">AIDS 2026</a>) taking place in Rio http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html Tue, 21 Jul 2026 10:00:00 -0400 A.23317141 A.26378697 A.50200944 GILD MRK O.00037438 O.00043238 O.00092067 O.37220915 O.39182271 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html <p class="bwalignc"> <b><i>–</i></b><i><b> Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP –</b></i> </p><p class="bwalignc"> <b><i>– Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir –</i></b> </p><p class="bwalignc"> <b><i>– Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54573930&newsitemid=20260720642268&lan=en-US&anchor=AIDS+2026&index=1&md5=c84579da5c0a7485df797bac17460af5" shape="rect">AIDS 2026</a>) taking place in Rio http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html Tue, 21 Jul 2026 10:00:00 -0400 A.23317141 A.26378697 A.50200944 GILD MRK O.00037438 O.00043238 O.00092067 O.37220915 O.39182271 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html <p class="bwalignc"> <b><i>–</i></b><i><b> Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP –</b></i> </p><p class="bwalignc"> <b><i>– Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir –</i></b> </p><p class="bwalignc"> <b><i>– Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Faids2026&esheet=54573930&newsitemid=20260720642268&lan=en-US&anchor=AIDS+2026&index=1&md5=c84579da5c0a7485df797bac17460af5" shape="rect">AIDS 2026</a>) taking place in Rio http://www.streetinsider.com/Press+Releases/Gilead+to+Present+New+HIV+Research+at+AIDS+2026+Across+Prevention%2C+Treatment+and+Cure/26793752.html Tue, 21 Jul 2026 10:00:00 -0400 A.23317141 A.26378697 A.50200944 GILD MRK O.00037438 O.00043238 O.00092067 O.37220915 O.39182271